Following last year’s Expert View on Astellas Pharma Europe’s Action on Fistula program, Christina Chale (pictured above, center), the company’s corporate communications director, writes about her visit to Kenya to see what difference is being made to the lives of women with obstetric fistula and how the program is delivering business as well as societal benefits.
“You have given us back our dignity.”
These words were spoken to us by Sarah Omega Kidangasi, an outreach worker who had received reconstructive surgery for obstetric fistula at the Gynocare Women’s and Fistula Hospital.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze